VRTX

CRISPR Therapeutics' expanding pipeline could unlock significantly more value by 2031. The article suggests a potential increase in company worth over the next five years.

FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available.

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Biotech experienced a sharp reversal, beating the S&P 500 by 22 points in three months. The piece questions whether the trade still has potential or if gains have already been taken.

CRISPR Therapeutics' $5.6B market cap and $1.78B net cash position make it an attractive acquisition target. The article notes that the CASGEVY platform validation strengthens this case.

Both Vertex and Regeneron could outperform the market over the medium term, but one appears to have a clear edge. The article compares the two biotech giants to determine which is currently better.

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals has a market

Next Phase of Geophysical Work Advances Priority Targets Following August Technical StudyVANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp.